Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
| Small Cap
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
N/A
Industry Median
N/A
Market Cap Median
N/A
P/B RATIO
N/A
Industry Median
N/A
Market Cap Median
N/A
P/S RATIO
N/A
Industry Median
N/A
Market Cap Median
N/A
Others
PEG RATIO
N/A
EV/EBITDA RATIO
N/A
Revenue GrowthAverageEBITDA GrowthAverageEPS GrowthAverageRevenue Growth
EBITDA Growth
EPS Growth
No Peer Data Is Available at This Moment.
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
No Stock Reports Available at This Moment.
Solara Active Pharma Sciences Ltd. is a leading Indian manufacturer of Active Pharmaceutical Ingredients (APIs) and Pharmaceutical Intermediates. Formed through a demerger, it serves both regulated and emerging markets globally, specializing in a diverse portfolio of complex and niche molecules for various therapeutic areas and also offers Contract Development and Manufacturing Organization (CDMO) services.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Solara Active Pharma Sciences Ltd's P/E ratio (TTM) is N/A, compared to the industry median of 35 and large cap median of 33.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Solara Active Pharma Sciences Ltd's P/B ratio is N/A, compared to the industry median of 5.50 and large cap median of N/A.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Solara Active Pharma Sciences Ltd's P/S ratio is 0.90, compared to the industry median of 3.80 and large cap median of N/A.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Solara Active Pharma Sciences Ltd's PEG ratio is N/A.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Solara Active Pharma Sciences Ltd's EV/EBITDA ratio is N/A.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Solara Active Pharma Sciences Ltd's ROE is N/A.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Solara Active Pharma Sciences Ltd's ROA is N/A.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Solara Active Pharma Sciences Ltd's ROCE is N/A.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Solara Active Pharma Sciences Ltd's operating margin is N/A.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Solara Active Pharma Sciences Ltd's net margin is N/A.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Solara Active Pharma Sciences Ltd's current ratio is N/A.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Solara Active Pharma Sciences Ltd's debt-to-equity ratio is N/A.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Solara Active Pharma Sciences Ltd's interest coverage ratio is N/A.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Solara Active Pharma Sciences Ltd's DPS is ₹0.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Solara Active Pharma Sciences Ltd's EPS is N/A.
(Source line: "Ratios as of 25 Sept 2026, based on last traded price of ₹N/A. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 2017 (formed via demerger)
Headquarters: Bengaluru, Karnataka
Core Offerings: Active Pharmaceutical Ingredients (APIs), Pharmaceutical Intermediates, Contract Development and Manufacturing Organization (CDMO) services
Stock Listing: NSE (SOLARA), BSE (541540)
Promoter: Khemka Family / Arrakis Investments
2017: Formed as an independent entity through the demerger of the Active Pharmaceutical Ingredients (API) businesses of Strides Shasun Ltd. (now Strides Pharma Science Ltd.) and Sequent Scientific Ltd. 2018: Successfully listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE), marking its debut as a publicly traded company. Present: Focused on expanding its API portfolio, strengthening manufacturing capabilities, and growing its presence in global regulated and emerging markets, with strategic divestments of non-core assets in recent years.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Active Pharmaceutical Ingredients (APIs) | Nearly 100% | Operating Profit |
Active Pharmaceutical Ingredients (APIs): Solara manufactures a diverse portfolio of APIs for various therapeutic areas, including anti-inflammatory, anti-retroviral, central nervous system, and general-purpose drugs.
Global Presence & CDMO: The company supplies APIs to both regulated markets (e.g., US, Europe) and emerging markets, offering Contract Development and Manufacturing Organization (CDMO) services for niche and complex molecules.
Puranam Siva Prasad (MD & CEO): Brings extensive experience in the pharmaceutical industry, having held leadership roles in manufacturing, operations, and business development across various global pharma companies.
Solara Active Pharma Sciences (Mauritius) Limited
Solara Active Pharma Sciences (USA) Inc.
Solara Active Pharma Sciences (Germany) GmbH
Pharmitzel Excipients Private Limited (step-down subsidiary)
Divestment of Vizag manufacturing facility (2023) and stake in Aurigene Oncology Ltd. (2023).
The Solara Active Pharma Sciences Ltd share price today is ₹N/A on NSE (SOLARA), as of 26 Sept 2026.
As of 25 Sept 2026, Solara Active Pharma Sciences Ltd share price is ₹N/A, with previous close ₹N/A. Today's range is ₹N/A to ₹N/A. The 52-week range is ₹422 to ₹774.
As of today, Solara Active Pharma Sciences Ltd's market cap is ₹N/A crore (Small Cap).
Solara Active Pharma Sciences Ltd's current P/E ratio is N/A, compared to the Financial Services sector average of 33.
Solara Active Pharma Sciences Ltd's current P/B ratio is N/A.
Solara Active Pharma Sciences Ltd's current dividend yield is N/A. Last dividend of ₹0.00 per share was declared on N/A.
Solara Active Pharma Sciences Ltd's EPS (TTM) is ₹N/A.
Solara Active Pharma Sciences Ltd. is a leading Indian manufacturer of Active Pharmaceutical Ingredients (APIs) and Pharmaceutical Intermediates. Formed through a demerger, it serves both regulated and emerging markets globally, specializing in a diverse portfolio of complex and niche molecules for various therapeutic areas and also offers Contract Development and Manufacturing Organization (CDMO) services.
Solara Active Pharma Sciences Ltd is promoted by Khemka Family / Arrakis Investments, holding N/A as of 25 Sept 2026.
Solara Active Pharma Sciences Ltd is listed on NSE (SOLARA) and BSE (541540). Its next quarterly results are expected on August 2024.
Capital Efficiency & Returns
